Research programme: G protein-coupled receptor modulator antibody therapeutics - Heptares Therapeutics/Kymab

Drug Profile

Research programme: G protein-coupled receptor modulator antibody therapeutics - Heptares Therapeutics/Kymab

Alternative Names: GPCR modulator monoclonal antibodies - Heptares/Kymab; GPCR targeting antibody therapeutics - Heptares/Kymab; KY 1051; KY 1062

Latest Information Update: 11 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics; Kymab
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jan 2018 Preclinical trials in Cancer in United Kingdom (Parenteral) before January 2018 (Kymab pipeline , January 2018)
  • 18 Apr 2016 Heptares Therapeutics and Kymab agree to co-develop and co-promote G protein-coupled receptor modulator antibody therapeutics in United Kingdom for Cancer
  • 18 Apr 2016 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top